Single-Gene Disorders: What Role Could Moonlighting Enzymes Play?  by Sriram, Ganesh et al.
Am. J. Hum. Genet. 76:911–924, 2005
911
REVIEW ARTICLE
Single-Gene Disorders: What Role Could Moonlighting Enzymes Play?
Ganesh Sriram,1,3 Julian A. Martinez,2,4 Edward R. B. McCabe,1,2,4 James C. Liao,3
and Katrina M. Dipple1,2,4
1Department of Human Genetics and 2Division of Medical Genetics, Department of Pediatrics, David Geffen School of Medicine,
3Department of Chemical Engineering, Henry Samueli School of Engineering and Applied Science, and 4Mattel Children’s Hospital,
University of California–Los Angeles, Los Angeles
Single-gene disorders with “simple” Mendelian inheritance do not always imply that there will be an easy prediction
of the phenotype from the genotype, which has been shown for a number of metabolic disorders. We propose that
moonlighting enzymes (i.e., metabolic enzymes with additional functional activities) could contribute to the com-
plexity of such disorders. The lack of knowledge about the additional functional activities of proteins could result
in a lack of correlation between genotype and phenotype. In this review, we highlight some notable and recent
examples of moonlighting enzymes and their possible contributions to human disease. Because knowledge and
cataloging of the moonlighting activities of proteins are essential for the study of cellular function and human
physiology, we also review recently reported and recommended methods for the discovery of moonlighting activities.
Introduction
We now recognize that single-gene disorders, with de-
ceptively simple Mendelian inheritance patterns, do not
always show evidence of predictable relationships be-
tween genotypes and phenotypes (Scriver and Waters
1999; Dipple and McCabe 2000a, 2000b). This has been
observed in the case of metabolic disorders such as glyc-
erol kinase deficiency (GKD [MIM 307030]), phenyl-
ketonuria (MIM 261600), and Gaucher disease (MIM
230800), in which the mutations identified in the ge-
nomes of affected patients do not correlate clearly with
their symptoms. This is a source of disappointment to
clinical geneticists, since it presents a serious challenge
to the concept that genotype can predict the clinical phe-
notype (Dipple and McCabe 2000b).
Previous reviews from our group have proposed three
reasons for the absence of a clear genotype-phenotype
relationship in such cases: the presence of indeterminate
ranges in protein activities (Dipple and McCabe 2000b),
the existence of modifier genes or loci that modulate the
phenotype (Dipple and McCabe 2000a), and the role
of systems dynamics (including flux through related
metabolic pathways) in imparting a phenotype that is
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not easily deduced from the genotype (Dipple et al.
2001a, 2001b; Clipsham et al. 2002; Clipsham and
McCabe 2003).
In this review, we point out an additional factor that
could contribute to the complexity of metabolic disor-
ders—the existence of moonlighting enzymes. “Moon-
lighting,” a term coined by Jeffery (1999), refers to the
phenomenon that many metabolic enzymes can exhibit
unrelated functional activities within or outside the cell.
The definition of moonlighting proteins excludes pro-
teins that result from alternative mRNA splicing, post-
translational modifications, and gene fusions; proteins
capable of utilizing multiple substrates (e.g., aldolase);
and proteins catalyzing multiple steps in the same meta-
bolic pathway (e.g., phosphofructokinase/fructose-2,6-
bisphosphatase); nevertheless, there are a few dozen
moonlighting proteins (Jeffery 2003b).
Examples of moonlighting activities include, but are
not limited to, transcriptional regulation and apoptosis.
If the gene of interest in a metabolic single-gene disorder
encodes a metabolic enzyme whose moonlighting activ-
ities are as yet unknown, and if one or more of these
moonlighting activities contribute to the phenotype of
the disorder, then this could result in a phenotype that
cannot be explained by the loss of the metabolic activity
of the enzyme, thus causing an apparent uncorrelation
between genotype and phenotype.
Here, we illustrate moonlighting proteins with spe-
cific examples and discuss their possible roles in disease.
We also review methods of discovery of moonlighting
activities and emphasize the need for reliable discovery
methods.
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Figure 1 High prevalence of moonlighting enzymes. Most metabolic enzymes in familiar pathways—for example, glycolysis (and glycerol
metabolism) (A) and the TCA cycle (B)—exhibit moonlighting activities. Moonlighting enzymes are shown in white font in gray boxes, and
their known moonlighting activities are listed on the side. Suspected moonlighting activities are marked with an asterisk (*). Metabolite
abbreviations are as follows: 1,3PG p 1,3-bisphosphoglycerate; 2PG p 2-phosphoglycerate; 3PG p 3-phosphoglycerate; AcCoA p acetyl
coenzyme A; Cit p citrate; DHAP p dihydroxyacetone phosphate; F1,6P p fructose-1,6-phosphate; F6P p fructose-6-phosphate; Fum p
fumarate; G3P p glycerol-3-phosphate; G6P p glucose-6-phosphate; GAP p glyceraldehyde-3-phosphate; Glu p glucose; Gly p glycerol;
ICit p isocitrate; Mal p malate; OAA p oxaloacetate; PEP p phosphoenolpyruvate; Pyr p pyruvate; SCoA p succinyl coenzyme A; Scnp
succinate; aKG p a-ketoglutarate. Enzyme abbreviations are as follows: ACO p aconitase; ALD p aldolase; CS p citrate synthase; ENOp
enolase; FH p fumarate hydratase; HK p hexokinase; IDH p isocitrate dehydrogenase; MDH p malate dehydrogenase; PFK p phospho-
fructokinase; PGK p phosphoglycerate kinase; PGM p phosphoglycerate mutase; PKp pyruvate kinase; STKp succinate thiokinase; TPIp
triose phosphate isomerase; aDHp a-ketoglutarate dehydrogenase. diff.p differentiation. Enzymes shown here but not discussed in the main
text (and their corresponding references) are HK (Fiek et al. 1982; Linden et al. 1982; Ostlund et al. 1983), PGK (Lay et al. 2000, 2002), CS
(Numata et al. 1991; Numata 1996), IDH (Elzinga et al. 1993; Chen et al. 2005), aDH (Chen et al. 2005), and STK (Chen et al. 2005).
Examples of Moonlighting Proteins
In this section, we highlight selected examples of meta-
bolic enzymes that have demonstrated moonlighting ac-
tivities. It should be noted that we present only a rep-
resentative sample of the numerous metabolic enzymes
that display additional functional activities. Previous re-
views provide exhaustive lists (Ramasarma 1994; Jeffery
1999, 2003a, 2003b, 2004b), and we have chosen to
draw attention only to moonlighting proteins that are
not covered in those reviews (aldolase, enolase, glycerol
kinase, and glycogen synthase kinase 3b), have addi-
tional moonlighting activities elucidated since those re-
views were published (aconitase and glyceraldehyde-3-
phosphate dehydrogenase), and/or are notable for the
variety of moonlighting activities they exhibit (glycer-
aldehyde-3-phosphate dehydrogenase and phosphoglu-
cose isomerase).
Figure 1 illustrates the high prevalence of moonlight-
ing among familiar enzymes. A metabolic map of gly-
colysis (fig. 1A) reveals that 7 of the 10 glycolytic en-
zymes exhibit various moonlighting activities. In addi-
tion, other metabolic enzymes closely linked to glycol-
ysis (e.g., glycerol kinase and fructose-1,6-bisphospha-
tase) also moonlight. Similarly, figure 1B shows that at
least seven of the eight enzymes of the tricarboxylic acid
(TCA) cycle have moonlighting or suspected-moonlight-
ing activities.
The diversity of nonenzymatic additional functions
exhibited by moonlighting enzymes is shown in figure
2. The moonlighting activities range from signal trans-
duction events, such as transcriptional regulation and
apoptosis; to growth and motility; to structural func-
tions, such as those of lens crystallins.
Aconitase
Aconitase is an enzyme of the TCA cycle, and it cata-
lyzes the reaction that converts isocitrate to a-ketoglu-
tarate (fig. 1B). Cytosolic aconitase also plays a role in
iron metabolism by functioning as an iron-responsive
element-binding protein (IREBP), which regulates the
mRNAs corresponding to ferritin, which is an iron-se-
questration protein, and the transferrin receptor, a pro-
tein involved in iron uptake (Kennedy et al. 1992; Rou-
ault et al. 1992). The aconitase and IREBP activities of
this protein are mutually exclusive and are dictated by
cytosolic iron levels. When iron levels in the cytosol are
low, aconitase loses its enzymatic activity and functions
as an IREBP (Kennedy et al. 1992). A recent study found
an inverse correlation between the iron-responsive ele-
ment-binding activity and the nonheme iron content in
the livers of various mammals (Starzynski et al. 2004).
The IREBP functions by binding to the iron-responsive
element, which is located in the 5′ UTR of ferritin mRNA
and in the 3′ UTR of transferrin receptor mRNA. This
binding regulates the translation initiation of ferritin
mRNA or the half-life of the transferrin receptor mRNA,
thus exercising control of iron metabolism (Basilion et
al. 1994; Jeffery 1999). Furthermore, it has been shown
recently that, in yeast, mitochondrial aconitase is essen-
tial for mtDNA maintenance and that this activity is
independent of catalytic activity or flux through aconi-
tase (Chen et al. 2005).
Aldolase
Aldolase is a glycolytic enzyme that catalyzes the
cleavage of fructose-1,6-bisphosphate into dihydroxy-
acetone phosphate and glyceraldehyde phosphate (fig.
1A). Lu et al. (2001, 2004) reported that aldolase binds
to vacuolar H-ATPase (V-ATPase) in yeast, and adolase
was found to be associated with intact V-ATPase in bo-
vine kidney microsomes and in osteoclast-containing
mouse marrow cultures. V-ATPases are essential for the
acidification of intracellular compartments and for pro-
ton secretion from the plasma membrane in kidney epi-
thelial cells and osteoclasts. Aldolase has been reported
elsewhere to bind to actin (Arnold and Pette 1970).
Enolase
Enolase catalyzes the conversion of 2-phosphoglycer-
ate to phosphoenolpyruvate in glycolysis (fig. 1A). It has
914 Am. J. Hum. Genet. 76:911–924, 2005
Figure 2 A representative sample of the wide variety of moonlighting activities of common metabolic enzymes. Suspected moonlighting
activities are marked with an asterisk (*). FHp fumarate hydratase; PKp pyruvate kinase; GSHp glutathione. Moonlighting proteins shown
here but not discussed in the main text (and their corresponding references) are CD26/dipeptidyl peptidase IV (CD26/DPPIV) (Boonacker and
Van Noorden 2003) and cytochrome C, ribosomal proteins, thymidilate synthase, and thymidine phosphorylase (Jeffery 2003b).
been reported to function as a plasminogen receptor
(Miles et al. 1991; Dudani et al. 1993; Nakajima et al.
1994) and a heat-shock protein and to bind to cytoskele-
tal and chromatin structures (Pancholi 2001). Enolase
serves as a crystallin in the eye lens (Wistow et al. 1988).
Recently, Wang et al. (2005) identified a-enolase as a
nuclear DNA-binding protein in the zona fasciculata of
the human adrenal cortex. The transfection of an a-
enolase expression vector into human adenocortical cells
enhanced the promoter activity of the type II 3b-hy-
droxysteroid dehydrogenase gene, which indicates that
enolase may have a functional role in regulating the ex-
pression of this gene (Wang et al. 2005).
Glyceraldehyde-3-Phosphate Dehydrogenase
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
has been discovered to have several moonlighting activi-
ties (Sirover 1999)—it has at least 10 distinct, confirmed
nonenzymatic activities apart from its enzymatic func-
tion of converting glyceraldehyde-3-phosphate to 1,3-
diphosphoglycerate (fig. 1A). GAPDH is the same pro-
tein as uracil DNA glycosylase, which repairs DNA by
excising uracil (Meyer-Siegler et al. 1991). It is also in-
volved in endocytosis (Robbins et al. 1995), microtubule
bundling (Kumagai and Sakai 1983), phosphate group
transfer (Kawamoto and Caswell 1986; Duclos-Vallee
et al. 1998; Engel et al. 1998), nuclear tRNA export
(Singh and Green 1993), and vesicular transport (Tisdale
2001). GAPDH plays a structural role in the eye, where
it acts as a lens crystallin (Jeffery 1999). It also binds to
biomolecules, including RNA (Ryazanov 1985), RNA
polymerase (Mitsuzawa et al. 2005), and diadenosine
tetraphosphate (Ap4A) (Baxi and Vishwanatha 1995),
one of whose functions is to decrease blood insulin levels
(Rusing and Verspohl 2004). Recently, GAPDH has also
been demonstrated to be important in sperm motility
and, therefore, in male fertility (Miki et al. 2004).
Moreover, GAPDH plays a significant role in apop-
tosis. This is apparent from a mounting body of indirect
and direct evidence (Berry and Boulton 2000; Tatton et
al. 2000). For example, GAPDH binds to Ap4A, which
is involved in apoptosis (Vartanian 2003; Wang et al.
2003). Low extracellular K levels in cerebellar granule
cell cultures that induced apoptosis also resulted in an
increase in GAPDH mRNA and protein (Sunaga et al.
1995). Furthermore, treatment with GAPDH antisense
oligonucleotides affected both GAPDH levels and ap-
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optosis, establishing a direct link between the two (Sun-
aga et al. 1995; Ishitani et al. 1997). Although the low-
ering of extracellular K levels can result in both ap-
optosis and necrosis (Berry and Boulton 2000), GAPDH
antisense treatment affected apoptosis only and did not
prevent necrosis (Ishitani et al. 1997).
The apoptotic activity of GAPDH involves the trans-
location of the protein into the nucleus (Sawa et al. 1997;
Shashidharan et al. 1999) and is independent of both its
glycolytic and uracil DNA glycosylase activities (Berry
and Boulton 2000). Although the exact mechanism of
nuclear translocation and subsequent initiation of ap-
optosis are not yet well understood (Chuang et al. 2005),
some recent evidence has suggested a potential mode of
action. This includes the binding of GAPDH to a nuclear
localization signal–containing protein, Siah, to initiate
nuclear translocation and an apparent change in the
structure of GAPDH after its nuclear translocation
(Chuang et al. 2005).
Also, GAPDH was recently shown to be involved in
the formation of Lewy body–like inclusions in cultured
cells and the concomitant apoptosis (Tsuchiya et al.
2005). Lewy bodies are intraneuronal proteinaceous cy-
toplasmic inclusions and are a pathological character-
istic of Parkinson disease, which is linked to apoptosis
of dopaminergic cells (Tsuchiya et al. 2005).
Glycerol Kinase
Glycerol kinase (GK) catalyzes the conversion of glyc-
erol to glycerol-3-phosphate (fig. 1A) and is known to
be an important enzyme in glycerol metabolism. Inde-
pendently, Okamoto et al. (1993) cloned the gene re-
sponsible for the ATP-stimulated translocation protein
(ASTP) from rat liver, and Huq et al. (1996) found that
ASTP had 99% homology to the amino acid sequence
of mouse GK. ASTP is an ATP-stimulated factor that
enhances the nuclear binding of the activated glucocor-
ticoid-receptor complex (Okamoto et al. 1984). Addi-
tionally, GK/ASTP has been shown to bind to histones
(Okamoto et al. 1989), to interact with porin or the
voltage-dependent anion channel on the outer surface of
the outer mitochondrial membrane (McCabe 1983; Ost-
lund et al. 1983), and to be a lysosomal stabilization
factor (Arai et al. 2002). Recently, our group has shown
that GK may have a role in apoptosis (Martinez and
McCabe 2004).
Glycogen Synthase Kinase 3b
Glycogen synthase kinase 3 (GSK3) was initially dis-
covered as a kinase involved in the regulation of glucose
metabolism, in which it phosphorylates glycogen syn-
thase A to glycogen synthase B. In mammals, it occurs
as two closely related isoforms, GSK3a and GSK3b. The
GSK3b isoform is highly expressed in neural tissue. It
has functions in various neuronal signal-transduction
pathways and is emerging as a promising drug target for
CNS therapies (Bhat et al. 2004). Most recently, GSK3b
has been reported to play a critical role in the establish-
ment and maintenance of neuronal polarity (Jiang et al.
2005; Yoshimura et al. 2005). In particular, it regulates
collapsin-response mediator protein 2, which is crucial
for axon outgrowth and for determining of the fate of
the axon and dendrites and, therefore, in establishing and
maintaining neuronal polarity (Yoshimura et al. 2005).
Lens Crystallins
Many crystallins present in the lens of the eye as re-
fractive proteins have been identified as well-known meta-
bolic enzymes, such as lactate dehydrogenase, argino-
succinate lyase, glutathione-S-transferase, enolase, and
aldehyde dehydrogenase (Ramasarma 1994; Piatigorsky
1998b, 2003; Jeffery 1999). A recent study that analyzed
the proteomes of human lens epithelial cells reported
high abundances of the aforementioned enzymes among
the proteins present, along with the glycolytic enzymes
aldolase, phosphoglycerate kinase, and triose phosphate
isomerase (Wang-Su et al. 2003). Lens crystallins are
believed to have been recruited as structural proteins
during the evolution of the eye (Piatigorsky 1998a, 1998b,
2003). Some crystallins may also serve additional func-
tions. For instance, aldehyde dehydrogenase is postu-
lated to function as a UV filter in the human lens, because
of its binding to nicotinamide adenine dinucleotide (Bate-
man et al. 2003).
Phosphoglucose Isomerase
Phosphoglucose isomerase (PGI) catalyzes the second
step in glycolysis, the conversion of glucose-6-phosphate
to fructose-6-phosphate (fig. 1A). Mammalian PGI also
functions as a neurotrophic factor, a neuroleukin (Cha-
put et al. 1988; Faik et al. 1988), an autocrine motility
factor (Watanabe et al. 1996), and a nerve growth factor
(Gurney et al. 1986), as well as a differentiation and
maturation mediator (Xu et al. 1996). Interestingly, not
all these activities are exhibited by PGI in other organ-
isms. For example, bacterial or yeast PGI does not ex-
hibit autocrine motility factor activity (Amraei and Nabi
2002).
Pyruvate Kinase
Pyruvate kinase mediates the final step of glycolysis—
the conversion of phosphoenolpyruvate to pyruvate (fig.
1A). As a metabolic enzyme, it is a homotetramer in
almost all organisms (Munoz and Ponce 2003). How-
ever, it can exist as a monomer, and its monomeric form
in mammalian muscle is a thyroid hormone–binding pro-
tein that regulates the transcriptional responses of the
thyroid-hormone receptor (Ashizawa et al. 1991, 1992).
Additionally, it can synthesize nucleotide triphosphate
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(NTP) under anaerobic conditions in bacteria (Saeki et
al. 1974; Sundin et al. 1996).
Switching between Functions
One or more factors may be responsible for the function
exhibited by a moonlighting protein. A partial list of
such factors includes cellular sublocalization, expression
in different cell types, presence inside or outside the cell,
oligomeric state, substrate or ligand concentration, bind-
ing sites, and phosphorylation. Although a similar list
was presented in an earlier publication by Jeffery (1999),
it is revisited here with recently elucidated examples.
Cellular Sublocalization
GAPDH functions as an enzyme outside the nucleus
but has an apoptotic function in the nucleus. Similarly,
GK plays an enzymatic role outside the nucleus and an
ASTP role within the nucleus. Aconitase functions as an
enzyme in the mitochondrion and the cytosol; however,
its compartmentation determines the nature of its moon-
lighting activity—it functions as an IREBP in the cyto-
sol and has an mtDNA maintenance function in the
mitochondrion.
Expression in Different Cell Types
Enolase functions as a glycolytic enzyme in most cell
types but also as a structural crystallin in the eye lens.
Furthermore, the DNA-binding function of enolase in
the human adrenal cortex was observed only in the zona
fasciculata and not in the zona reticularis (Wang et al.
2005).
Presence Inside or Outside the Cell
Ku70/Ku80 is a protein complex involved in DNA
strand–break recognition and repair within the cell, but
it participates in proteolytic processes outside the cell
(Muller et al. 2005).
Oligomeric State
Pyruvate kinase exhibits metabolic activity as a tetra-
mer and thyroid hormone–binding activity as a monomer.
Concentration of Ligand or Substrate
As mentioned above, iron levels determine whether
aconitase functions as an enzyme or as an IREBP.
Binding Sites
Moonlighting proteins may employ different binding
or catalytic sites for different functions. For example,
ceruloplasmin, an oxidase that participates in copper
metabolism, moonlights as a copper-independent glu-
tathione peroxidase (Bielli and Calabrese 2002), and it
employs distinct catalytic sites to bind to the substrates
of either function. Similarly, mammalian InsP6 kinase (an
inositol phosphate kinase) binds to the guanine nucleo-
tide exchange factor, and this binding does not require
the catalytic site of the enzyme (Shears 2004).
Phosphorylation
It is likely that phosphorylation is sometimes respon-
sible for switching between functions. There is recent
evidence that phosphorylation of PGI at the residue
Ser185 by protein kinase CK2 causes it to lose its en-
zymatic activity but does not affect its function as an
autocrine motility factor (Yanagawa et al. 2005). How-
ever, there are instances in which phosphorylation is
critical for both activities of a protein, as in the case of
aconitase, in which loss of phosphorylation at Ser711
results in loss of both the aconitase and the IREBP ac-
tivities (Fillebeen et al., in press).
Why Do Moonlighting Activities Exist?
There are two nonexclusive hypotheses about the exis-
tence of moonlighting activities: that these activities sim-
ply evolved and were not lost and that they offer definite
advantages to the cell or organism (Jeffery 1999).
Evolution
Since many moonlighting proteins are familiar meta-
bolic enzymes (fig. 1) and are present in a wide variety
of organisms that have evolved over billions of years, it
is likely that the additional activities of the proteins
evolved, possibly to make use of unused sites on the
protein surface. It is notable that active sites usually do
not occupy a large fraction of the protein surface area,
leaving considerable solvent-exposed surface that can be
recruited for other functions (Jeffery 1999).
A recent study of lens crystallins (Piatigorsky 2003)
provides interesting insights into the evolution of moon-
lighting activities. Ancestral enzymes may have been re-
cruited as crystallins, following a gene duplication (with
one gene encoding a protein with enzymatic activity and
the other gene encoding a lens-specific crystallin) or a
regulatory change (high expression of the ancestral pro-
tein in the lens), or both. Gene duplication is evidenced
by the presence of two genes encoding a-crystallin/heat-
shock protein (aA and aB), which are situated on sepa-
rate chromosomes in mice and humans. The protein en-
coded by the aB-crystallin gene has remained a heat-
shock protein, is expressed constitutively, and is induc-
ible by stress. In contrast, aA-crystallin is expressed pre-
dominantly in the lens and is not stress inducible. How-
ever, certain other crystallins, such as -crystallin/lactate
dehydrogenase and g-crystallin/a-enolase, are encoded
by single-copy genes, indicating that a transcriptional
regulatory change conducive to high expression in the
lens must have preceded the evolution of the refractory
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role for the protein. The fact that many crystallin genes
are regulated by similar transcription factors (e.g., Pax-
6, retinoic acid receptors, maf, Sox, AP-1, and cAMP
response element B) reinforces the idea that the common
feature of lens-specific expression may have played an
important role in the recruitment of diverse enzymes as
lens crystallins (Piatigorsky 2003).
Advantages to the Cell or Organism
Moonlighting activities can also be advantageous to
the cell. One simple reason is that they reduce the num-
ber of proteins that the organism has to synthesize—
thus, less energy is expended for DNA replication, and
the genome is more compact (Jeffery 1999). The cell can
benefit from the increased complexity with relatively
fewer genes. Additionally, moonlighting can serve to co-
ordinate related cellular activities or to switch between
pathways (Jeffery 1999). For example, the interaction
of aldolase with V-ATPase links two related pathways:
the ATP-producing glycolytic pathway and the ATP-hy-
drolyzing proton pump (Lu et al. 2004; Sautin et al.
2005). The use of moonlighting activities to switch be-
tween proximate pathways is exemplified by mitochon-
drial aconitase (Chen et al. 2005) and rat liver mito-
chondrial Lon protease, an ATP-dependent protease that
degrades certain mitochondrial proteins but that is also
a mitochondrial chaperone (Jeffery 1999).
Moonlighting Proteins and Human Disease
As mentioned above, moonlighting proteins can add to
the complexity of single-gene disorders. In a majority of
cases, there is as yet no confirmed evidence that the non-
metabolic activity of a moonlighting enzyme encoded by
a disease gene is responsible for the phenotype of a dis-
order. Nevertheless, there are strong indicators that this
may be occurring, as discussed below.
GAPDH
We noted above that GAPDH plays a role in apop-
tosis. Excessive apoptosis is involved in many neuro-
degenerative diseases, such as Huntington disease (MIM
143100), Alzheimer disease (MIM 104300 and 104310),
Parkinson disease (MIM 168601), and brain ischemia
(Chuang et al. 2005), and recent findings support the
role of GAPDH in these diseases. For example, nuclear-
aggregated GAPDH was found in neurons of affected
areas in postmortem brains of individuals who had Alz-
heimer disease (Tsuchiya et al. 2004). A proteomic an-
alysis of neurofibrillary tangles in Alzheimer disease by
mass spectroscopy identified GAPDH to be associated
with neurofibrillary tangles (Wang et al., in press). A
linkage analysis of patients with late-onset Alzheimer
disease (MIM 104310) revealed an association with
SNPs in the GAPDH gene, indicating that this gene is a
risk factor for the disease (Li et al. 2004). Furthermore,
potential drugs for treatment of Alzheimer disease, such
as tetrahydroaminoacridine and ONO-1603, suppress
GAPDH expression and its nuclear translocation in rat
brain neurons undergoing apoptosis in cultures (Katsube
et al. 1996, 1999).
These results suggest a role for GAPDH-induced ap-
optosis in Alzheimer disease. The role of GAPDH in
Parkinson disease is indicated by its participation in the
formation of Lewy body–like inclusions in cultured cells
and subsequent apoptosis (Tsuchiya et al. 2005). For a
full review that identifies the role of GAPDH in the afore-
mentioned neurodegenerative diseases, see the article by
Chuang et al. (2005).
Xanthine Oxidoreductase
Xanthine oxidoreductase (XOR) is the rate-limiting en-
zyme in purine catabolism. Vorbach et al. (2002) noted
that XOR is expressed at very high levels in the lactating
mammary epithelium and suggested that it may serve a
structural role. They confirmed this hypothesis by study-
ing XOR-deficient mice. XOR/ females, although
they appeared healthy, were unable to maintain lacta-
tion, and their pups died of starvation. Further investi-
gations showed that the mammary epithelium collapsed
in the knockout mice, and this resulted in premature
involution of the mammary gland. XOR/ mice, on
the other hand, were runted and did not survive beyond
6 wk. Although this shows that XOR is necessary for
survival, it does not indicate whether the protein’s meta-
bolic function (purine catabolism) or moonlighting func-
tion (structural role in mammary epithelium) is respon-
sible for survival.
However, previous and recent reports provide strong
indications that XOR plays a moonlighting structural
role in the mammary gland. For example, XOR protein
levels selectively increased in mammary tissue during
pregnancy and lactation (McManaman et al. 1999,
2002), and XOR in human mammary epithelial cells had
low specific activities despite high mRNA levels (Page
et al. 1998; Harrison 2004), suggesting that XOR may
be playing a nonenzymatic role.
Recent findings have also shown that XOR structur-
ally interacts with milk-fat globule proteins, including
butyrophilin and adipophilin (McManaman et al. 2004;
Ogg et al. 2004). Ogg et al. (2004) have suggested that
the butyrophilin-XOR interaction may contribute to the
formation of a protein complex that stabilizes the milk
droplet.
PGI
Deficiency of PGI is an autosomal recessive genetic
disorder (MIM 172400), which manifests as hemolytic
anemia but can also include neurological defects (Kugler
et al. 1998). This is consistent with the enzyme’s moon-
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lighting role as a neuroleukin. A severe form of this
disorder has been reported in which the mutations A59C
(H20P) and T1016C (L339P) cause substitutions by pro-
lines, with the consequent misfolding of the protein and
the loss of both the enzymatic and neuroleukin activities.
However, a less severe form of this disorder involved the
mutations A1166G (H389R) and C1549G (L517V) lo-
cated at the subunit surface, which affected the enzyme
activity of PGI but not the neuroleukin activity. Not
surprisingly, the latter mutations were not associated
with neurological defects (Kugler et al. 1998). This ex-
ample clearly illustrates that moonlighting activities of
an enzyme can help to explain the apparent lack of ge-
notype-phenotype correlation in a disease involving de-
ficiency of the enzyme.
ERCC2
Mutations in the excision-repair, complementing
defective, in Chinese hamster, 2 gene (ERCC2 [MIM
126340], formerly known as the “xeroderma pigmen-
tosum group D” gene), result in three disorders with
markedly different clinical features (Lehmann 2001).
Xeroderma pigmentosum (XP [MIM 278730]) is char-
acterized by several skin abnormalities that range from
excessive freckling to multiple skin cancers, with a high
risk of skin cancer in affected individuals. Cockayne syn-
drome (MIM 216400) is characterized by severe ca-
chectic dwarfism, mental retardation, microcephaly, and
retinal and skeletal abnormalities. Trichothiodystrophy
(TTD [MIM 601675]) is characterized by sulfur-de-
ficient brittle hair, mental retardation, unusual facies,
ichthyotic skin, and reduced stature, as well as sun sen-
sitivity, but there are no reports of skin cancer. In ad-
dition, the XP-causing alleles of the gene were not ob-
served in individuals with TTD, and vice versa (Petrini
2000).
The distinct phenotypes are now explained by the
finding that ERCC2 encodes a protein that has two dis-
tinct functions. It functions as a DNA helicase involved
in the repair of DNA damaged by exposure to ultraviolet
light, and it is also a subunit of TFIIH, a basal tran-
scription factor (Lehmann 2001). XP is caused princi-
pally by defects in nucleotide-excision repair—that is,
by the enzymatic (helicase) function of the gene product.
In contrast, TTD and Cockayne syndrome are caused
by defects in transcription (Lehmann 2003).
GK
GKD is a disorder that occurs because of mutations,
deletions, or insertions in the GK gene (MIM 300474)
on Xp21 (Dipple et al. 2001b). It can occur either as
complex GKD, a contiguous-gene-deletion syndrome, or
as isolated GKD. Isolated GKD can be symptomatic or
asymptomatic (Sjarif et al. 2000; Dipple et al. 2001b).
Thus far, there has been no satisfactory correlation be-
tween genotype and phenotype in patients with isolated
GKD (Sargent et al. 2000; Dipple et al. 2001b). In fact,
the exact same mutation has been observed in a symp-
tomatic and an asymptomatic individual (Sargent et al.
2000), and this discrepancy has also been observed in
two brothers with the identical mutation (Blomquist et
al. 1996). The GK enzymatic activities in lymphoblas-
toid cell lines or fibroblasts were similar for the symp-
tomatic and asymptomatic individuals. Also, mapping
of the individuals’ GK mutations to the Escherichia coli
three-dimensional protein structure did not distinguish
the symptomatic from the asymptomatic individuals
(Dipple et al. 2001b).
As noted above, GK is a moonlighting enzyme, and
it is likely that one of its additional functional activities,
rather than its enzymatic activity, may help explain the
GKD symptomatic phenotype. In particular, the role of
GK in transcriptional regulation through nuclear trans-
location of the glucocorticoid receptor complex, or the
role of GK in apoptosis, could provide clues to explain
the complexity of GKD.
However, moonlighting might not by itself account
for the perplexing fact that individuals or siblings with
the same mutation exhibit different phenotypes. This
could be a result of the action of modifier genes, as
postulated elsewhere (Dipple and McCabe 2000a). Also,
it is likely that the modifier genes interact with the moon-
lighting function of the protein, rather than the enzy-
matic function.
Succinate Dehydrogenase and Fumarate Hydratase
Succinate dehydrogenase (SDH [MIM 602690]) and
fumarate hydratase (or fumarase [MIM 136850]) cata-
lyze consecutive steps in the TCA cycle. Recently, it was
discovered that a gene that predisposes to inherited mul-
tiple uterine leiomyomata (fibroids) (MIM 150800) and
papillary renal cell cancer (MIM 650839) is the same as
the gene encoding fumarate hydratase (Tomlinson et al.
2002). Along the same lines, germline SDH mutations
were shown to be associated with paraganglioma (MIM
168000) and pheochromocytoma (MIM 171300) (As-
tuti et al. 2001). These findings suggest that these en-
zymes, directly or indirectly, play specific tumor-sup-
pressing roles, which supports the potential existence of
moonlighting activities for these metabolic enzymes,
since the tumor suppression cannot be explained by the
metabolic activity of the enzymes (Jeffery 2003a).
However, firm evidence is still lacking, and the inves-
tigation of the nature of the tumor-suppressing mecha-
nism should shed more light on this interesting finding.
A recent study showed that, at least in the case of SDH,
metabolic activity may be indirectly responsible for tu-
mor suppression; succinate, which accumulates as a re-
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sult of SDH deficiency, inhibits hypoxia-inducible factor
1a (HIF-1a) prolyl hydroxylases, thereby stabilizing HIF-
1a, which causes angiogenesis and tumor growth (Selak
et al. 2005).
Aconitase
There is a myopathy (MIM 255125) that is associated
with aconitase and SDH deficiency and in which the
affected individual has an abnormal deposition of iron
in the mitochondria (Haller et al. 1991; Hall et al. 1993).
This affected individual experienced exertional muscle
fatigue, dyspnea, and cardiac palpitations. Hall et al.
(1993) have speculated that the dynamic Fe-S center of
mitochondrial aconitase may respond to mitochondrial
iron levels, as is seen with IREBP/aconitase. Although
there is no evidence that the moonlighting function of
aconitase is responsible for the myopathy, a recent article
by Lipinski et al. (2005) shows that the IREBP function
of this protein can have far-reaching effects, including
DNA damage. Specifically, Lipinski et al. (2005) showed
that increases in cellular iron (due to an increase in IR-
EBP activity and a decrease in aconitase activity) may
result in DNA damage induced by hydrogen peroxide
through the Fenton reaction.
Elucidation of Moonlighting Activities
Serendipity
Serendipity has been a major contributor to the iden-
tification of moonlighting activities thus far. For ex-
ample, the 10 moonlighting activities of GAPDH listed
above were reported independently by 13 different re-
search groups in five countries (see citations in the “Glyc-
eraldehyde-3-Phosphate Dehydrogenase” section). Fur-
thermore, 11 of those 13 research groups identified an
unknown protein as GAPDH, so this enzyme was not
even the initially intended subject of the study. A glimpse
at articles that first reported moonlighting activities of
many other proteins also reveals that many of the find-
ings were unforeseen.
Nevertheless, the possible role of moonlighting pro-
teins in metabolic disorders and the consequent urgency
to identify them necessitates systematic methods of dis-
covery. Below are some methods that have been reported
and recommended.
Mass Spectrometry
Mass spectrometry (MS) is a powerful technique in
proteomics. Jeffery (in press) has suggested the use of
MS to identify potential moonlighting proteins. MS can
provide two principal indicators of moonlighting activi-
ties. First, the presence of a protein in an unexpected
location in the cell, in an unexpected cell type, or in an
unexpected multiprotein complex could point to possi-
ble moonlighting activities. For example, large amounts
of the glycolytic enzymes aldolase, phosphoglycerate ki-
nase, and triose phosphate isomerase were detected in
the proteomes of human lens epithelial cells by use of
MS (Wang-Su et al. 2003), and this result indicates a
possible role for these proteins in the lens. Second, if
there are high protein expression levels that do not cor-
relate with an enzyme’s measured metabolic activity, that
may indicate that the protein is performing a function
distinct from its known metabolic activity (Jeffery, in
press).
Since MS can be used in a high-throughput fashion,
it holds promise for detection of possible moonlighting
activities. However, it can provide only an indication,
and further experimentation is essential to confirm
whether the protein actually moonlights and to deter-
mine the nature of the moonlighting activity.
Proteome Arrays
A recent study reported that Arg5,6—a mitochondrial
enzyme involved in arginine biosynthesis—binds to DNA
and regulates transcription in yeast (Hall et al. 2004).
That study employed a proteome array; a microarray con-
taining 6,500 protein preparations of 5,800 yeast pro-
teins was probed with genomic yeast double-stranded,
fluorescently labeled DNA. Arg5,6 was identified among
the positives found. Since transcriptional regulation by
a moonlighting protein can play a potentially important
role in disease, this technique of discovery is valuable,
subject to the easy availability of proteome arrays for
higher organisms.
Bioinformatic Approaches
Sequence-analysis algorithms, such as those used in
BLAST, PROSITE, EMOTIF, PROTLOC, and many
other programs, rely on sequence motifs to identify pro-
tein function (Jeffery 2004b). A recent study attempted
to identify moonlighting activities of common moon-
lighting proteins by employing 11 different sequence-
analysis algorithms (Gomez et al. 2003). It was observed
that success rates were only moderate at best. For
GAPDH, 7 of 11 algorithms identified the enzymatic
function, and only 3 of 11 algorithms identified the ura-
cil DNA glycosylase function. Among the algorithm-
based programs, PSI-BLAST performed reasonably well
in identifying moonlighting activities.
Network component analysis (NCA) is another bioin-
formatic approach that identifies possible new functions
by recognizing novel connectivities between genes and
transcription factors (Liao et al. 2003; Kao et al. 2004).
NCA has been used with gene-expression microarray
data from E. coli and yeast to uncover hidden regulatory
signals and possible new network relationships when
only partial knowledge of the underlying network to-
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pology exists. In E. coli, ∼70% of randomly selected
transcription-factor networks could be identified by NCA
(Liao et al. 2003). NCA provides a powerful approach
to mining microarray data and to gaining insight into
new network connectivities and, therefore, novel puta-
tive functions.
Insights from the Structure-Function Relationships
of Moonlighting Proteins
Many recent studies have focused on the elucidation
of the structure-function relationships of moonlighting
proteins. For example, a recent study of aconitase/IREBP
(Fillebeen et al., in press) reported that, in HEK293 cells,
phosphorylation of this protein at the residue Ser711
had devastating effects on both the enzymatic and IREBP
activities, which indicates that Ser711 is a critical residue
for the control of the activities of this protein. However,
the exact mechanism by which phosphorylation controls
the activities of this protein is yet to be elucidated.
The insights into multifunctionality obtained from
three-dimensional crystal structures of moonlighting pro-
teins (reviewed by Jeffery [2004a]) are of particular in-
terest. For example, Lee et al. (2003) reported the crystal
structure of PutA proline dehydrogenase, which moon-
lights as a transcriptional regulator of its own gene. Lee
et al. (2003) noted that the structure contains a helical
domain with three helices arranged in a helix-turn-helix
pattern found in other DNA-binding domains, and they
suggested that this could represent the DNA-binding do-
main responsible for transcriptional repression, although
further experiments are needed to confirm this suppo-
sition (Jeffery 2004a).
Lee et al. (2004) investigated functional domains of
the Brevibacillus thermophilus Lon protease (Bt-Lon),
which is involved in the degradation of damaged and
short-lived proteins, in ATPase and chaperone-like ac-
tivities, and in DNA binding. This protein includes an
N-terminal domain, a central sensor- and substrate-dis-
crimination domain, and a C-terminal protease domain.
Lee et al. (2004) prepared seven mutants of Bt-Lon, each
of which lacked one or more domains. The truncation
of the N-terminal domain led to the failure of oligo-
merization and the inactivation of proteolytic, ATPase,
and chaperone-like activities, suggesting that oligomeri-
zation is essential for the catalytic and chaperone-like
activities. Furthermore, gel-mobility shift assays indi-
cated that the substrate-discrimination domain is in-
volved in DNA binding.
Summary and Outlook
In this review, we highlighted some key and recently
reported moonlighting enzymes that exhibit an astound-
ing variety of additional functional activities. We also
summarized mechanisms employed by moonlighting pro-
teins to switch between functions, as well as hypotheses
about the existence of moonlighting proteins.
The moonlighting activities of familiar metabolic en-
zymes include signal-transduction events such as tran-
scriptional regulation and apoptosis, and it is likely that
the moonlighting activities of these enzymes may con-
tribute to the complex phenotype of a given disorder.
It is very likely that the complex phenotypes observed
in many single-gene disorders that cannot be explained
solely by the loss of the enzymatic activity of the protein
might be explained by a moonlighting activity of the
protein.
The identification and cataloging of all activities of
proteins in the proteome is therefore essential for under-
standing human genetic diseases. Thus, high-through-
put methods of identification of moonlighting functions
are required. Although most moonlighting activities re-
ported to date were recognized by serendipity, the use
of systematic methods is slowly gaining prominence,
and we reviewed above some methodologies that hold
promise in this area.
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